Previous studies on AML have mainly focused on mutant genes, namely, FLT3, IDH2, NPM1, RUNX1, TP53, and DNMT3A (Ofran, 2014; Sudhindra and Smith, 2014; Ohgami et al., 2015; Papaemmanuil et al., 2016), miRNA (Ali Syeda et al., 2020) and mRNA (Blagden and Willis, 2011). This evidence concerns the gene TP53 and acute myeloid leukemia.